Alright, any last words from the panelist? On DCB or any other topics we covered today? Oh yeah, I'd like us to add that of course we are using drug balloons. We have brown, we had myotronic, and what was not is a special. They're very good. Drug balloons are not for dilatation. Now you prepare and you dilate, and then finally I even even with kissing we we we lose the profile so you prepare the region very well and then finally just to deliver the deadline. Yep, I will certainly present. I think you you want it. You're absolutely right and you want to make sure that with the balloon you have a good result. There's no there's no point deploying a drug coated balloon. If you have a dissection after a regular balloon inflation, right? You might as well stamp that. If you have a complication, there's no point using drug coated balloon. Thank you for the great talk. In the peripheral world, the paclitaxel coated balloons that is following the user is tendency for like slow reflow or increased mortality because of microemboli compared to serolimus erudite therapy. I think that's in peripheral, right? Yeah, that has not been found in coronary. OK, that's yeah. There's lots of reasonable good data that has not shown that in coronary work. Is it true that anything new they first tried on the Europeans, then on the Canadians, and then Americans come third? Well, you know, like we're kind of in between, right? So so it makes sense, doesn't it? For Brazil has drug looting balloons for several years, so. Well, we still have freedom here, so it's good. So we're going to get drug coated balloons down the road. Great, I'm there identified. So this point is again. So last time for today and then I'm leaving. You know this is why we're trying to make another code for doing complex angioplasty. So there's a big difference between doing an LED stent, you know, one stent and in and doing any kind of this work. And no one is getting valued for this work right now that we're all do, you know, that we all do. And maybe it's 10% of the time. I feel like it's a heck of a lot more than 10% of the time that we're doing, you know, extensive work to preserve these branches. And, you know, and like the case you just showed, you know, that's a left main stent. The first case, you know, that that's an incredible amount of work, you know. And we need to keep this in mind when you're doing your surveys, pay attention and think about this kind of level of work that you have to do and how to translate that in. And then we're going to have to put a new set of surveys that'll be coming over the next couple of years as we get the drug code of balloon technology. So, you know, think about all the time it takes to prepare the lesion, to then, you know, treat the lesion properly, the extra time that you have the balloon up. I want everyone thinking about all these things. So I'll keep saying it all the time. So, you know, for the for the ruck survey, you're my first question. First question to Vlad. Vlad, you mentioned about the end platelet therapy after the balloons. Do you have if you have equivalent results in a stent and a drug looting balloon, do you think that those that patient could have a shorter depth regime? Absolutely. You don't have any metal. So it's a good point. I have no metal. So absolutely. Now you have you have metal in the main vessel, right? There are some situations where you might choose a drug looting balloon in a complex high risk patients because you don't want any dual end platelet therapy. But I don't think that means that they actually have to be on it. But if you've used a drug looting stent, you know, a simpler procedure rather than bifurcation procedure, you don't need that long anyway. Choose a stent that has data for short depth. There are some that have data for one month, some that have data for three months, some that don't have that. Right. So. OK, everyone, what a great session. Thank you for all your participation.

drug balloons

medical procedures

drug-coated balloons

angioplasty procedures

end platelet therapy